Key messages from the e-ESO faculty The pandemic is here. Italy is further along the curve than the rest of Europe. That gives other countries a small breathing space to prepare for when the tsunami [more]
Obesity is overtaking tobacco as the leading preventable cause of cancer. Oncologists have an important role to play in informing patients and directing them towards assistance in making lifestyle changes. Antonio Di Meglio reviews the [more]
Immunotherapy agents are being used to treat a growing range of cancers, but emerging evidence from randomised trials and clinical practice shows very different patterns of toxicity compared to chemotherapy. Jean-Marie Michot reviews what doctors [more]
People with incurable cancer need doctors who offer them hope but also give them a clear idea of what is realistically possible. Doctors can find it hard to be both empathic and honest when the [more]
Traditional approaches to generating clinical evidence rely on recruiting large numbers of patients into trials. Paolo Bruzzi reflects on the challenges of designing and analysing clinical trials in rare cancers, and reviews the potential for [more]
What does our growing understanding of the molecular subtypes of gastric and oesophageal cancers, and the results of recent trials testing multimodal therapies, mean for the way we classify, diagnose and treat these tumours? Jonas [more]
Testing for hereditary mutations that increase the risk of cancer is important for risk reduction, early detection and choice of treatment. Ephrat Levy-Lahad offers an overview of what we know ‒ and what remains uncertain [more]
Cancer patients are put at risk unless the surgeons who operate on them understand the principles of the disease, work closely with other oncology disciplines, and know which patients need to be referred to high-volume [more]
A chromosomal alteration present in almost all patients with Hodgkin lymphoma makes the disease uniquely vulnerable to PD-1/PD-L1 immune checkpoint blockers. Astrid Pavlovsky reviews the trial evidence and clinical experience, and looks to the future [more]
PARP inhibitors are the first class of drugs to exploit a new concept in oncology – synthetic lethality. Alexandra Leary explains the rationale, reviews the trial evidence and clinical experience, and looks to their future [more]
Stimulating development of more and better paediatric cancer drugs will be key to making progress, particularly in some of the hardest-to-treat childhood cancers. Gilles Vassal, past-President of the European Society for Paediatric Oncology, outlines emerging [more]
Engaging the body’s own immune system in controlling cancer has long been an aspiration for cancer researchers and clinicians. This overview looks at progress towards that goal, and how it is changing the paradigm of [more]
The state of the art on the diagnosis and management of cancer of the pancreas and hepatobiliary system was the focus of the 3rd St Gallen Gastrointestinal Cancer Conference, held earlier this year under the [more]